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  Oncological management of skeletal metastases has 
changed dramatically in the last few decades. A signifi-
cant number of patients survive for many years with their 
metastases.
  Surgeons are more active and the technical repertoire is 
broader, from plates to intramedullary devices to (tumour) 
endoprostheses.
  The philosophy of treatment should be different in the 
case of a trauma-related fracture and a pathological frac-
ture. A proper algorithm for establishing a diagnosis and 
evaluation of prognostic factors helps in planning the sur-
gical intervention.
  The aim of palliative surgery is usually to eliminate pain 
and to allow the patient to regain his/her mobility as well 
as to improve the quality of life through minimally inva-
sive techniques using life-long durable devices.
  In a selected group of patients with an oncologically con-
trolled primary tumour site and a solitary bone metastasis 
with positive prognostic factors, which meet the criteria 
for radical excision (approximately 10% to 15% of the 
cases), a promising three to five years of survival may be 
achieved, especially in cases of metastases from breast and 
kidney cancer.
  Spinal metastases require meticulous evaluation because 
decisions on treatment mostly depend on the tumour 
type, segmental stability, the patient’s symptoms and 
general state of health.
  Advanced radiotherapy combined with minimally invasive 
surgical techniques (minimally invasive stabilisation and 
separation surgery) provides durable local control with a 
low complication rate in a number of patients.
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Introduction
Cancer is the second most frequent cause of death. 
According to the data of the Scandinavian Skeletal Metas-
tasis Registry,1 the incidence of cancer has increased by 
18% during the last decade, but due to improved treat-
ment, cancer mortality rates have remained nearly con-
stant (+2%).
The third most important filter for cancer metastases 
after the lungs and the liver is the skeletal system. There 
has been a change in paradigm in the treatment of meta-
static disease of the bone. In the past, mostly palliative 
treatments, radiotherapy and pain relief were favoured. 
Nowadays, modern diagnostic tools (PET-CT, whole 
body MRI, etc) are included in the follow-up protocols 
allowing for early detection of bony metastases. Besides 
improved chemotherapy and radiotherapy, new tar-
geted therapy such as bisphosphonates and denosumab 
(antigen against RANKL) reduce skeletal-related events 
(SREs). A broad spectrum of surgical options is available 
for reconstruction of defects. Many of the osteosytheses 
may be performed by minimally invasive techniques. All 
these factors have resulted in a significantly longer sur-
vival for metastatic patients, even with multiple metasta-
ses allowing for an increase in SREs, e.g. fracture, spinal 
cord compression, hypercalcaemia, etc, which lead to a 
substantial burden for both the patients and financially 
for society.
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This review discusses the diagnostic work-up, prognos-
tic factors, survival and surgical management of the meta-
static lesions affecting the spine and long bones of the 
extremities.
Metastatic diseases of the long bones
Diagnostic algorithm
Many authors2-7 recommend rather similar diagnostic 
work-up protocols for potential metastatic diseases. These 
flow charts help orthopaedic surgeons and oncologists to 
establish the correct diagnosis and plan the most favour-
able treatment accordingly. Our own protocol is pre-
sented in figure 1.
In cases of an aggressive bone lesion, in a patient with 
a history of oncologically controlled cancer, the basic 
question is the number of the metastases. Plain 
radiographs, isotope bone scan, MRI,4,5 or in certain cases 
PET-CT, should be used for staging. When we are sure that 
the lesion is solitary, we should evaluate patient- and 
tumour-related prognostic factors (see ‘Prognostic factors 
and survival’ below). Biopsy is only necessary when other 
diseases, i.e. tumour-like lesions, raise a differential diag-
nostic problem or if ablative surgery is planned. Evaluat-
ing laboratory findings, the patient’s condition and the 
local stage of the tumour, we can decide whether to per-
form radical or palliative surgery.
In cases with multiple bone metastases, surgery is 
always palliative. The question here is the local status of 
the involved bone regardless of the patient’s condition. 
The fracture risk can be determined according to Mirel’s 
score system.8 Biopsy (fine needle aspiration biopsy or 
core) is only necessary when there are two different types 
of primary cancers present in the clinical history of the 
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Fig. 1 Diagnostic algorithm at impending fracture (known primary tumour).
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patient. In cases with impending fracture, a careful evalu-
ation of all circumstances is necessary, e.g. the type of the 
primary tumour, the chemo-sensitivity, the radiosensitiv-
ity, the metastatic load and the general status of the 
patient, available and effective drugs, etc. Not all impend-
ing fractures, especially not those of non-weight-bearing 
bones of the upper extremity, must be operated on as 
prophylaxis.9
When the site and type of the primary cancer is 
unknown, routine laboratory tests should be comple-
mented by tumour markers: prostate specific antigen; thy-
roid function tests; and myeloma screen. The orthopaedic 
surgeon should keep in mind that breast, thyroid, lung, 
kidney and prostate cancer present as the primary type of 
more than 70% of all bone metastases.1 Whole-body MRI, 
CT of the chest, abdomen and pelvis, bone scintigraphy 
and PET-CT are helpful in locating the primary tumour. 
PET-CT has high sensitivity but low specificity. It is, how-
ever, useful in cancers with a high risk of bone metastases, 
e.g. breast cancer, kidneys, etc.6 Biopsy is often required 
for histological examination, which is also helpful in find-
ing the primary tumour site, but should be the last proce-
dure in the diagnostic work-up because it weakens the 
affected bone and can lead to a pathological fracture.
Approximately 20% of patients with bone metastases 
are referred with an actual pathological fracture to the 
trauma unit. It is important to recognise the pathological 
nature of the fracture. The treatment policy should differ 
in pathological and trauma-related fractures.2 While in 
trauma cases a rapid osteosynthesis is required for union 
of the fracture, treatment of the pathological fracture is 
usually less urgent. It is more important to assess the 
patient’s general condition, the primary tumour site and 
prognostic factors than to determine the precise surgical 
procedure, e.g. plating with cement augmentation/pros-
thesis, etc. In this way, irredeemable failures, such as 
intramedullary nailing spanning the entire length of the 
bone in cases of primary bone sarcoma, can be avoided. 
Even though patients with a pathological fracture of the 
extremity are very difficult, examination by endoscopy for 
gastrointestinal malignancies, by MRI or bone scan, clini-
cal history and lab tests, and CT for the chest, abdomen 
and pelvis, as well as radiographs, are helpful to screen 
the five most frequent primary tumours.
Prognostic factors and survival
Potential prognostic factors have been extensively investi-
gated by several authors.1,2,10-14
Willeumier et al,2 Katagiri et al,11 Bollen et al,14 Toyoda 
et  al15 and others also presented a predictive model for 
patient survival based on scoring systems. forsberg 
et al10,16 applied the Bayesian Belief Network for estimat-
ing the survival in patients with skeletal metastases and 
found this model accurate and robust.
It is, however, very difficult to estimate the actual 
patient’s survival in terms of months or years with bone 
metastatic disease.17 Different factors play a role if the 
long bones or spine are affected. Most authors17-19 still 
regard the type of primary tumour as one of the most pre-
dictive prognostic survival factors. Based on large popula-
tion studies, Cox regression analysis indicated the 
following further important factors: the Karnofsky/Eastern 
Co-operative Oncology group performance status; the 
presence of visceral metastases; the haemaglobin count; 
and number of metastases. Pathological fracture as a 
prognostic factor is a controversial issue. Some authors 
did not find a statistically proven relevant correlation in 
this regard,1,20-22 while others,19,23 including Kirkinis et al18 
in thier meta-analysis of the literature, found a worse out-
come if pathological fracture occurred. In the Kaplan-
Meier univariate analysis, the axial location, the time 
interval between the diagnosis of cancer and that of the 
metastases (more than three years), additional conserva-
tive treatments and type of surgery were also significant 
factors in cases with solitary metastases.20,24,25 In another 
study,19 age, gender, method of surgical fixation and loca-
tion in different long bones did not play a significant role.
The highest ratio of solitary metastases, 38.8%, was 
observed in the Scandinavian Skeletal Metastasis Registry 
(n = 1195) among patients with renal cell cancer.1 Logi-
cally, one would assume that the best five-year survival is 
also in this group following complete surgical resection, 
but this is not the case. This may be due to the fact that in 
most cases there is an acceleration of the process in a few 
years and additional conservative treatments (radiother-
apy, interferon, etc) have little influence on overall sur-
vival. Lin et  al26 found that the clear-cell histological 
sub-type was associated with better survival. In this study, 
the fuhrman grade27 of the initial tumour was not a pre-
dictive factor. Our data supported this20 and we could, 
however, demonstrate a good correlation between the 
grade of the metastatic lesion and survival. This may be 
explained by our finding that when comparing the fuhr-
man grade of the initial tumour, progression in the grade 
of metastases was found in 40%, downgrading in 30% 
and the same grade in 30%. This explains that the final 
outcome for the patient depends more on the new cell 
population of the metastases than on the grade of the 
original renal cell cancer. Toyoda et  al15 and Szendrői 
et  al20 found a significant difference between synchron 
and metachronbone metastases and survival. When the 
interval between the diagnosis of the first tumour and 
metastasis was 24 months or more, the ratio of survival 
was higher.
According to data from a large patient population (n = 
7064), about 22% of women with breast cancer will 
develop metastases in the bone.28 Risk factors for develop-
ing a bone metastasis were tumour size (> 5 cm), higher 
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tumour grade, sub-type of the tumour (lobular carci-
noma) and number of positive lymph nodes. for those 
patients with metastases in the bone, factors influencing 
survival were the extent of the disease (multiple locations, 
visceral metastases) and duration of the symptoms in the 
series from Dürr et al.21 Other authors,29 in a multivariate 
Cox regression model, found oestrogen receptor positiv-
ity, solitary bone metastasis and biphosphonate treatment 
positive prognostic factors. Weiss et al23 reported age over 
60 years and a haemaglobin level less than 110 g/L as 
negative factors.
Bone metastases from lung cancer and melanoma 
have the worst outcomes in terms of survival (Table 
1).1,15,19,20,21,23,26,29-37 The former mostly presents in multi-
ple forms and the mean survival is under one year.32 Sugi-
ura et al32  found the histological sub-type adenocarcinoma, 
solitary lesions, lack of metastases to the appendicular 
bone, good patient general health status and the use of 
chemotherapy and targeted therapy (epithelial growth 
factor receptor inhibitor) as factors influenced survival in a 
positive way.
Some data on recent studies of the survival rates of can-
cer patients with operated skeletal metastases are summa-
rised in Table 1.1,15,19,20,21,23,26,29-37 In studies where all 
types of primary tumour were included, the one-year sur-
vival rates were in the range of 40% to 50%, with signifi-
cantly lower rates than in cases of breast, kidney, prostate 
and differentiated thyroid cancer metastases but higher 
than in lung cancer metastases. The one-year survival 
rates in breast and kidney cancers (between 45% and 
59%) are high and promising, but these decrease within 
the first five years to a range of 8% to 20%. The best five-
year results were achieved when solitary metastases were 
operated on extensively.
Surgical treatment
Surgery is usually not the primary choice of treatment in 
bone metastases. In multiple bone metastases in particu-
lar, treatment starts with palliative chemo-, radio- or hor-
mone therapy, isotopes or new targeted therapies 
according to the nature of the primary tumour. SREs can 
be effectively reduced by administration of bisphospho-
nates and denosumab.
The main goals of surgical treatment are to alleviate the 
pain, to prevent an imminent fracture, to perform an oste-
osynthesis in cases of a pathological fracture, to restore 
patient mobility and to improve the patient’s quality of 
life.
Intolerable pain and the presence of a pathological 
fracture are clear indications for surgery. It is, however, 
more contradictory in cases withan impending fracture. 
Many aspects, such as patient general health, the primary 
tumour and its histology and the effectiveness of other 
non-surgical treatments for this special kind of metastasis, 
should be evaluated before deciding to operate on an 
impending fracture. On the one hand, surgical interven-
tion carries risks for the patient and also affects immune 
status. On the other hand, it is not certain that pathologi-
cal fractures really occur during an effective non-surgical 
treatment or if the patient survives this event. This con-
cern is also reflected in the statistical data: in the 1195 
patients operated on for metastases, 74.2% had a patho-
logical fracture and 18.3% had an impending fracture.1
The metastatic load is different in the different skeletal 
areas. According to the large statistics of the Skandinavian 
Skeletal Metastasis Registry,1 the femur is affected in 64%, 
the humerus in 21% and the pelvis in 9%. Less than 1% 
occurred in the region of the hands and feet. Three- 
quarters of the lesions appear in the proximal part of the 
Table 1. Survival rates (%) of cancer patients with operated skeletal metastases
Reference Patients Primary tumour Median survival 
(mths)
6 mths 
(%)
1 yr 
(%)
2 yrs 
(%)
3 yrs 
(%)
5 yrs (%) 10 yrs (%)
Lin et al 200726 295 Renal cell cc 47 30 11  
hwang et al 201430 135 Renal cell cc 72 45 28  
Toyoda et al 200715 50 Renal cell cc 12 37  
Szendrői et al 201020 64 Renal cell cc 58 39.5 30 19.2; solitary 35.5  
Dürr et al 200221 70 Breast cc 59 36 13; solitary 39 7;
Ahn et al 201329 110 Breast cc 55 solitary 34.9
Weiss et al 201423 301 Breast cc 45 27 8  
Oster et al 201331 621 Breast cc 66.3 32.8  
Sugiura et al 200832 118 Lung cc 9.7 59.9 36 11  
Weiss and Wedin 201133 98 Lung cc 3 24 13 6  
Oster et al 201331 477 Lung cc 19 2.5  
Ratasvuori et al 20131 1107 All types of primary tumour 58 41 2  
harvey et al 201234 158 All types of primary tumour 51 29  
Mavrogenis et al 201235 110 All types of primary tumour 54 30 20 16  
Wedin et al 201236 208 All types of primary tumour 40 21 16  
hansen et al 200419 474 All types of primary tumour 39 26 18  
Nakayama et al 201437 40 Thyroid cc (differentiated) 77 64 45
cc, cell carcinoma
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femur, whereas in the humerus the diaphysis is the most 
frequently affected area.
Today, there are many different surgical tools for osteo-
synthesis and reconstruction of bony defects. The type of 
the primary (oncologically controlled or not) tumour, the 
patient’s general health status, other prognostic factors 
for expected survival and the local extent of the metastasis 
all play a role in planning the surgery. On rare occasions, 
e.g. solitary metastasis, a small lesion or when the tumour 
can be excised without a demanding procedure, the 
tumour should be excised completely to avoid further 
local complications. In most cases, however, an intrale-
sional approach with minimally invasive technique is justi-
fied for an end-of-life solution to avoid re-operations for 
complications.2,4
More than two-thirds of the femoral metastases appear 
in the proximal epi-metaphysis. Most authors favour nor-
mal long-stem cemented endoprosthesis designs or 
modular tumour endoprostheses in these cases, which 
allow the patient immediate mobility and are associated 
with fewer complications than intramedullary nails or 
plates.34,38,39 In cases of acetabular involvement, the clas-
sification according to harrington40 is useful. In this the 
treatment options are adapted to the severity and location 
of destruction.41,42 In the diaphysis of long bones, a plate, 
an intramedullary nail or a prosthesis may be implanted. 
All of these methods have their advantages and disadvan-
tages.43,44 for short-term life expectancies, intramedullar 
nailing with locking screws introduced by minimally inva-
sive technique and augmented by bone cement is opti-
mal. The patient may load the extremity immediately; 
post-operative radiotherapy, if necessary, may be started 
early on. The incidence of fatigue fracture, however, 
increases with time.9,25,34,45 for the treatment of metasta-
ses located near the knee joint, intramedullary nails and 
angulated plates with screws augmented by bone cement 
are good options for patients with short-term life expec-
tancies, whereas endoprosthesis should be used for 
patients with better prognosis.22 The relatively high price 
of these types of tumour endoprostheses should, how-
ever, be taken into consideration.
good results are described by Weiss et  al,46 with a 
cemented plate technique for fixation of proximal patho-
logical fractures of the humerus, whereas Wedin et  al36 
recommended a hemi-prosthesis for more destructive 
proximal humeral lesions and interlocking intramedullar 
nailing for the treatment of pathological fractures of the 
diaphyseal segment.
The incidence of complications associated with surgery 
of metastatic lesions of the bone is rather high, with authors 
reporting a range of 9% to 22% for the humerus36,46,47 and 
10% to 30% for the femur.1,4,22,24,39 These are mostly 
related to the poor quality of bone, failed implant selec-
tion, progression of the disease, the condition of the 
patient, but also dislocation of the prosthesis, loosening, 
periprosthetic infection and fracture of the implant.
Spinal metastases
Skeletal metastases most frequently occur in the vertebral 
column.48 The incidence of symptomatic spinal metasta-
ses is continuously growing with the increasing incidence 
of cancer and the associated survival.49 Due to the particu-
lar anatomy and biomechanics of the spine, the early diag-
nosis and adequate management of a spinal metastasis is 
crucial in the patient’s quality of life. The diagnostic evalu-
ation of a suspicious spinal secondary lesion contains 
some recently developed steps which are major corner-
stones of the therapeutic planning. The indication for sur-
gery is a key issue and it is strongly related to the clinical 
appearance and the overall prognosis. In the last few 
years, new techniques have been introduced, such as 
minimally invasive and stereotactic body radiotherapy, to 
achieve long-term local control with reduced morbidity.
Diagnostic cornerstone: stability
In addition to the diagnostic process applicable for any 
skeletal metastases, the evaluation of a spinal metastasis 
has to be completed by the determination of the biome-
chanical stability of the spine. Instability is associated 
with consequent pathological fracture and neurological 
impairment which significantly worsen the patient’s 
Table 2. Spinal Neoplastic Instability Score (SINS)
Score
Location
Junctional (occiput-C2, C7T2, T11-L1, L5-S1)
Mobile spine (C3-C6, L2-L4)
Semirigid (T3-T10)
Rigid (S2-S5)
3
2
1
0
Pain
Yes
Occasional pain but not mechanical
Pain-free lesion
3
1
0
Bone lesion
Lytic
Mixed
Blastic
2
1
0
Radiographic spinal alignment
Subluxation/translation present
De novo deformity (kyphosis/scoliosis)
Normal alignment
4
2
0
Vertebral body collapse
>50% collapse
<50% collapse
No collapse with >50% body involved
None of the above
3
2
1
0
Posterolateral involvement of spinal elements
Bilateral
unilateral
None of the above
3
1
0
Total score
Stable
Potentially unstable
unstable
0-6
7-12*
13-18*
*SINS score of 7 or higher requires consultation with a spine surgeon
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quality of life as well as survival. Early recognition of 
unstable lesions is crucial in the treatment choice, but the 
evaluation of stability is challenging because both radio-
logical and clinical findings have to be considered. 
Tumorous spinal instability can be defined as “the loss of 
spinal integrity as a result of a neoplastic  process that is 
associated with movement-related pain, symptomatic or 
progressive deformity, and/or neural compromise under 
physiological loads”.50 The first evidence-based, compre-
hensive and easy-to-use system for the evaluation of the 
stability of the spinal metastases was published in 2010 
by the Spine Oncology Study group (SOSg).50 The Spinal 
Instability Neoplastic Score (SINS) is a scoring system 
based on six features of the metastasis (Table 2). The sum 
of these parameters gives the SINS score (0 to 18), where 
the higher score indicates the more instable lesion. The 
SINS was developed to help the primary healthcare pro-
vider to decide whether the patient has to be referred to a 
spine surgeon or not. Consultation of a spine surgeon is 
advised for lesions with a SINS score of 7 or more (poten-
tially unstable and unstable lesions). The reliability and 
validity of SINS were tested in different, independent 
studies. The SOSg members published a near-perfect 
intra- and interobserver reliability for the total SINS score 
and high sensitivity (95.7%) and moderate specificity 
(79.5%) for the binary SINS score (stable versus (poten-
tially) unstable lesions) comparing the binary score with 
consensus opinion (benchmark).51 The multidisciplinary 
study group of the AOSpine Knowledge forum on 
Tumors (AOSpine Kf) conducted two studies to deter-
mine the properties of the SINS among radiologists and 
radiation oncologists,52,53 where substantial intra- and 
interobserver reproducibility of the binary SINS score was 
found in both clinician groups. Three independent stud-
ies published further evidence on the clinical use of the 
SINS score.54-56 The SINS has been adopted in several 
guidelines and clinical studies so far.57,58 The SINS was 
also included in two clinical decision frameworks for 
patients with spinal metastasis. The Neurologic, Onco-
logic, Mechanical stability, Systemic disease criteria 
(NOMS)59 as well as the Location, Mechanical instability, 
Neurological status, Oncological history, Physical status 
framework (LMNOP)60 advise the use of the SINS for the 
assessment of the stability of the lesion. A number of 
studies have been published concerning the clinical prog-
nostic value of the SINS in the last few years. A higher 
SINS score was significantly associated with the need for 
re-irradiation61 and with occurrence of spinal adverse 
events62 after radiation therapy of vertebral metastases. 
Survival after surgical management was found not to be 
associated with SINS score, but consequent vertebral 
compression fracture in cases with a higher SINS score 
significantly reduced quality of life.63-65
Prognostic factors and survival
A number of high quality studies have recently been pub-
lished about the use of different prognosis systems in case 
of spinal metastases. Bollen et al66 compared six prognos-
tic scoring systems on survival after the diagnosis of a spi-
nal metastasis. They analysed the clinical data of 1379 
patients. Overall median survival was 5.1 months with a 
high range (0.8 to 18.6) depending on the histology of 
the primary tumour. There was also a big difference in the 
expected survival among the three most common histo-
logical types. Since a long survival can be expected in the 
case of the most common (28%) breast cancer metastasis 
(median 18.6 months), the second most common type, 
lung cancer, showed a short survival (median 2.0 months), 
while the third most common histology (prostate) showed 
a medium-long survival (median 7.4 months). This large 
study underlies the most important oncological principle 
in survival estimation: ‘tissue is the issue’, i.e. the patient’s 
life expectancy is mostly determined by the histology of 
the primary tumour. Not surprisingly, this factor is the 
primary prognostic factor in all of the previously pub-
lished prognostic systems for spinal metastasis. Bollen 
et  al67 reported that consideration of the general health 
status of the patient and the presence of visceral metasta-
ses combined with the primary tumour profile has given a 
simple scoring system (Table 2); its performance in sur-
vival estimation is better compared with the formerly pub-
lished systems.66 The Bollen-score forms four categories (A 
to D) where survival dramatically decreased (29.8, 16.5, 
4.9 and 1.7 months median survival in categories A, B, C 
and D, respectively). The patient’s general health status 
characterised by the Karnofsky score is also a strong pre-
dictor for the quality of life in surgicallytreated patients.68 
Choi et al68 clearly showed that patients with a low Kar-
nofsky score (< 60) before the surgery could not benefit 
from the surgery regarding their quality of life independ-
ent of the pre-operative neurological status. Verlaan et al69 
analysed the characteristics of the patients who survived 
less than three months or more than two years after the 
surgery for spinal metastases in a large cohort (n = 1266). 
They found that increased age and Karnofsky score were 
associated with short survival, while lower number of lev-
els included in the spinal surgery and primary tumour 
type were related to long survival.
Surgical treatment
Radiation and surgical therapy are the two most effective 
options for the local control of spinal metastases. Both 
therapeutic modalities have been developed significantly 
over the past ten years, so the proper indication, treat-
ment choice and timing can give significantly longer local 
control with fewer complications for the patients than 
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before. A few algorithms for the indications and treatment 
choice have been recently published; nevertheless, none 
of them has been validated in a randomised prospective 
study. The multidisciplinary team of the Memorial Sloan-
Kettering Cancer Center has developed and published the 
NOMS decision framework, which is a comprehensive 
combination of the previously described significant fac-
tors, resulting in a clinically applicable and clear system 
(fig. 2).59 Parts of this decision-supporting framework 
have to be individually assessed for all patients diagnosed 
with spinal metastases, however, the access to the differ-
ent treatment options show a huge diversity nationally 
and internationally. Neurologic assessment indicates the 
degree of the spinal cord/nerve root compromise and the 
associated neurological deficit. Degree of epidural spinal 
cord compression (ESCC) is the key element in treatment 
choice, but the timing and progression of the neurological 
symptoms specifies the indications for an emergency 
treatment. A strong recommendation as a result of a 
recent systematic review of the AOSpine Kf has been pub-
lished concerning the need and urgency of the surgical 
decompression. According to this study, a patient with 
neurologic deficit from a ESCC resulting in loss of ability to 
ambulate requires urgent surgical decompression if there 
is no oncological or medical contra-indication.70 Diagno-
sis should be expeditious and surgery should be prompt 
to improve the probability of neurological recovery.
Oncological assessment mostly means the considera-
tion of the possibility for radiotherapy. Radiosensitivity of 
the tumour, previous radiotherapy and availability for 
radiotherapy have to be taken into account during the 
decision process. Solid tumours show a wide range of 
radiosensitivity. Breast, prostate and ovarian carcinomas 
are usually sensitive to radiotherapy, while renal, thyroid, 
colon and non-small-cell lung carcinomas, sarcoma and 
melanoma exhibit less, total or partial radioresistency.
Stereotactic radiosurgery (SRS) has to be used in cases 
with radio-resistant histology to achieve durable local 
Low-grade ESCC
No myelopathy
High-grade ESCC
+/-myelopathyN
eu
ro
lo
g
ic
Radiosensitive
Radioresistant/
previously radiated
O
n
co
lo
g
ic
Stable
UnstableM
ec
h
an
ic
al
Able to tolerate
surgery
Unable to tolerate
surgery
Sy
st
em
ic
Radiation therapy
cEBRT
SRS
ESCC: epidural spinal cord compression
SRS: stereotactic radiosurgery
cEBRT: conventional external beam radiationtherapy
Decompression/ 
Separation surgery
Stabilization
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spinal metastatic tumors.Oncologist 2013;18:744-751).59
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control.71,72 The SINS is advised to assess the mechanical 
stability. unstable lesions require stabilisation surgery. 
use of minimally invasive surgical techniques, such as 
percutaneous stabilisation, use of tubular retractors and 
mini-open approaches as well as percutaneous cement 
augmentation of pathological, stable but painful verte-
bral body fractures, are strongly advised to reduce the 
peri-operative complication rate.73 The last element of 
the NOMS framework is the systemic assessment which 
means the prediction of the patient’s ability to tolerate 
the proposed intervention. Comorbidities, general health 
status and tumour burden have to be assessed. The mini-
misation of the surgical intervention can make the sur-
gery safer and feasible for the patients. Therefore, the 
minimally invasive separation of the tumour tissue from 
the dural sac (separation surgery) with post-operative 
SRS radiotherapy would be the optimal treatment choice 
in a high number of cases, providing safe and effective 
local control.73
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